Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-15,800
Closed -$3.79M 3116
2021
Q4
$3.79M Buy
15,800
+7,800
+98% +$2.01M 0.02% 381
2021
Q3
$2.26M Buy
+8,000
New +$2.62M 0.01% 653
2020
Q3
Sell
-1,400
Closed -$374K 1899
2020
Q2
$374K Buy
+1,400
New +$421K 0.01% 895
2020
Q1
Sell
-12,300
Closed -$3.65M 796
2019
Q4
$3.65M Sell
12,300
-17,500
-59% -$4.86M 0.16% 111
2019
Q3
$6.94M Buy
29,800
+27,200
+1,046% +$6.33M 0.33% 47
2019
Q2
$608K Buy
+2,600
New +$600K 0.04% 373

Other funds holding BIIB

HRT Financial's BIIB Position: Q1 2026 in Review

HRT Financial sold out of Biogen (BIIB) in Q1 2026, closing a stake of 384,265 shares — an estimated $67.6M sold.

HRT Financial first reported a position in BIIB in Q1 2015 and held it in 20 quarters. The position peaked at $67.6M in Q4 2025. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • HRT Financial reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 384,265 Biogen shares in Q1 2026, an estimated $67.6M.
  • HRT Financial first reported a position in Biogen in Q1 2015 and held it in 20 quarters.
  • HRT Financial's Biogen position peaked at $67.6M in Q4 2025.
  • 1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.